Skip to content
NeuroTechGuide

Neuralink registers PRIME2 feasibility study that adds people with chronic stroke

The new US study plans to implant up to 10 adults with spinal cord injury, ALS or chronic ischemic stroke and test computer control with the N1 implant.

In briefImplantsClinical trials

Neuralink has registered PRIME2, an early feasibility study that for the first time lists chronic ischemic stroke alongside spinal cord injury and ALS. The ClinicalTrials.gov record, first posted November 10, plans to enroll about 10 adults at up to five US sites, with the University of Miami listed as recruiting. Stroke participants must be at least 12 months past their stroke and have lasting weakness in their formerly dominant arm. The robot-implanted N1 device sits in the motor cortex and is tested for control of a cursor or virtual keyboard.

The main measure is serious device-related adverse effects through 90 days, with about two years of follow-up. It is a single-group safety study, so it will not show whether the implant helps people recover movement.

Learn more: Motor cortex · Neuralink

Share:XLinkedInBlueskyEmail

More news